Monitor for IND submission and Phase 1 trial initiation in 2027, which are the next key catalysts. The $6.1M cash runway is tight for a pre-revenue biotech, so watch for potential dilutive financing events.
Price Chart
Executive Summary
Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is expected to enter the clinic in 2027. The company reported cash of $6.1M as of June 30, 2026, with a runway to mid-2027. The filing is a routine business update with no new material financial data or clinical results, but the cash runway and pre-revenue status are notable risks for a $2M market cap company.
Key Facts
- Cash of $6.1M as of June 30, 2026, with runway to mid-2027.
- Lead program IM1240 (cappedCD3x5T4xNKG2A) expected to enter the clinic in 2027.
- Pre-IND meeting completed; IND submission planned for 2027.
- Second program IM1305 (cappedCD3xTROP2xNKG2A) in preclinical development.
- Market cap of $2M as of filing date.
Financial Impact
Cash of $6.1M provides runway to mid-2027; no revenue reported.
Risk Factors
- Cash runway only to mid-2027, requiring additional financing before clinical data.
- All programs are preclinical or early clinical, with no approved products or revenue.
- Low market cap ($2M) increases volatility and risk of delisting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-087226 |
| Document: ea0301142-6k_purple.htm | 0001213900-26-087226 |
| Document: 0001213900-26-087226-index-headers.html | 0001213900-26-087226 |
| Document: 0001213900-26-087226-index.html | 0001213900-26-087226 |
| Document: 0001213900-26-087226.txt | 0001213900-26-087226 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.44 (−17.24%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.44 (−27.27%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.44 (−7.10%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.44 (+0.70%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.44 (−63.45%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.44 (−68.63%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.44 (−68.35%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access